UK: National AIDS Trust calls for the NHS to provide earlier HIV treatment

In a statement on Tuesday, BHIVA and EAGA stated how treatment as prevention reduces HIV transmissions. By using HIV drugs to reduce the levels of the virus in their system people with HIV can become virtually non-infectious.

Deborah Jack, chief executive of NAT said: “A number of people with HIV want to start treatment early to lessen the chances of passing the virus on, meaning less worry for them but also fewer HIV transmissions, saving the NHS many hundreds of thousands of pounds.

“NAT approached BHIVA and EAGA to investigate the scientific basis for treatment as prevention. It’s great to see this work come to fruition and to see these respected medical bodies endorse treatment as a way to tackle the rising numbers of people living with HIV in the UK.

Read More

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below